Apollomics (APLMW) Stock Price, News & Analysis

Company Overview

Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and potential commercialization of novel oncology therapies. Since its founding, the company has concentrated on creating targeted and immuno-oncology candidates designed to address unmet needs in solid tumors. Apollomics maintains headquarters in the United States with key research operations in China, leveraging a dual-site strategy to accelerate global development timelines.

The company’s pipeline encompasses a range of therapeutic modalities, including monoclonal antibodies, antibody-drug conjugates and bispecific constructs. Apollomics applies proprietary target-identification and antibody-engineering platforms to advance multiple programs from preclinical stages into Phase 1 and Phase 2 clinical trials. Its lead candidates are being evaluated in various solid tumor indications, with data readouts expected to inform next-stage development and potential registration strategies.

With operations spanning both the U.S. and China, Apollomics is positioned to navigate regulatory pathways in major markets while leveraging cost-efficient R&D infrastructure. The company’s management team comprises experienced executives with backgrounds in oncology drug development, clinical operations and regulatory affairs. Apollomics continues to explore strategic collaborations to broaden its pipeline and maximize the clinical and commercial potential of its drug candidates.

Key Stats

• Today's Range: $0.0116 to $0.0116
• 50-Day Range: $0.0111 to $0.0199
• 52-Week Range: $0.01 to $0.23
• Volume: 2,563 shs
• Average Volume: 55,136 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/24/2026
• Next Earnings (Estimated): 9/24/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:APLMW
• CIK: 1944885
• Web: www.apollomicsinc.com
• Phone: 650-209-4055
• Fax: N/A
• Employees: 59
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $8.50 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A